Merck will begin a major, critical study of the new coronapneumonia drug in September.

Although vaccines now look promising, they do not help patients who have been infected with the new coronavirus,media reported. The world still lacks a new treatment for coronary pneumonia that accelerates recovery, prevents complications and reduces the risk of death. Redsewe does play a role in some cases, but it’s expensive, scarce and hard to make. Dexamethason is cheap but not enough to save every patient’s life. Blood thinners can reduce the risk of clotting and eliminate some complications, but they do not in themselves cure new coronary pneumonia.

Merck will begin a major, critical study of the new coronapneumonia drug in September.

Other promising antibody therapies are now under study, some of which have been studied in human trials. Merck is testing an antiviral drug and is expected to begin a major, critical study in September.

“We may start doing very large, critical studies in September, so these studies will be important,” Roger Perlmutter, the company’s president, said on the company’s second-quarter earnings conference call. The drug, called MK-4482, was developed with Ridgeback Biotherapeutics. Perlmutter noted that Merck does not want to send sporadic data on the drug’s performance in The Second Phase II trial.

The company is also working on two vaccines, which will also be in clinical trials in the near future.

The MK-4482 is Merck’s most advanced new coronapneumonia treatment, according to a report by C and EN at the end of May. But MK-4482 is not always called. BioSpace noted that before the name change, the antiviral drug was called EIDD-2801.